Skip to main content
. Author manuscript; available in PMC: 2011 Sep 14.
Published in final edited form as: J Neuroimmunol. 2010 Jul 23;226(1-2):192–193. doi: 10.1016/j.jneuroim.2010.06.016

Table 1.

Clinical and demographic data of patient specimens.

Subject Age and Gender Disease
duration
(years)		 MS course AGS score1
MS-1 38/F NA RRMS 10.0
MS-2 65/M NA CPMS2 14.5
MS-3 43/F 20 CPMS2 11.9
MS-4 39/F 13 CPMS2 11.0
CSF-MS3 41/F 7 RRMS 10.94
CSF-OND5 58/2F:1M NR NR 4.56
PB-MS7 41/F <1 RRMS 2.08

Abbreviations: MS: multiple sclerosis, CSF: cerebrospinal fluid, OND: other neurological disease, PB: peripheral blood, F: female, M: male, NA: not available, NR: not relevant, RRMS: Relapsing-remitting MS, CPMS: Chronic progessive MS,

1

Number of VH4 sequences in AGS calculations: MS-1=20; MS-2=12, MS-3=9, MS-4=30, CSF-MS=128, CSF-OND=15, PB-MS=40

2

Pathology reports for these patients state “chronic progressive” with no additional history provided to determine whether these patients had primary or secondary progressive MS.

3

CD19+ CSF B cells were collected from 10 RRMS patients and 1 PPMS patient as published in (Cameron et al., 2009).

4,6,8

AGS score analysis from (Cameron et al., 2009). Scores represent averages of each cohort.

5

CD19+ CSF B cells were collected from 3 OND patients as published in (Cameron et al., 2009).

7

CD19+ peripheral B cells were collected from 3 RRMS patients as published in (Cameron et al., 2009).